Sirolimus for Colon Polyposis in PTEN Hamartoma Tumor Syndrome
Sirolimus has promise for reduction of colon polyp burden in PHTS, but side effects may limit usage. Future treatment trials in rare polyposis syndromes would benefit from the involvement of multiple centers to allow for improved recruitment.
Authors
- Peter P. Stanich (ORCID: https://orcid.org/0000-0002-6844-640X)
- Hisham Hussan (ORCID: https://orcid.org/0000-0002-8646-8370)
- Maegan E. Roberts (ORCID: https://orcid.org/0000-0002-0292-2557)
- Kebire Gofar (ORCID: https://orcid.org/0009-0005-8721-1445)
Institutions
- The Ohio State University Wexner Medical Center (US)
- University of California Davis Medical Center (US)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.14309/ctg.0000000000000871
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00